EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII

Andreas Hillarp, Pål A Holme, Erik P Wåland, Marie S Le, Carola E Henriksson, Geir E Tjønnfjord, Ragnhild J Måseide

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.07.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Andreas Hillarp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway; Department of Translational Medicine, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The immunogenicity, safety, and efficacy of recombinant factor VIII (rFVIII) have gained increasing interest after the introduction of extended half-life products with various modifications of the rFVIII molecule, such as covalent attachment of polyethylene glycol (PEG). Anti-PEG antibodies may be associated with a temporary reduction of FVIII recovery, but according to previous studies, they usually disappear after continuous dosing. Anti-PEG antibodies with an inhibitory capacity have never been demonstrated in patients treated with PEGylated rFVIII products. OBJECTIVES: To routinely switch from standard half-life to PEGylated extended half-life rFVIII products in patients with hemophilia A. METHODS: From December 2022 until May 2023, 83 adults with hemophilia A attending Oslo Haemophilia Comprehensive Care Centre received a test dose with a PEGylated rFVIII product to switch treatment. Four patients presented with decreased recovery without the presence of an FVIII inhibitor. Accordingly, we performed a variant inhibitor test utilizing different rFVIII concentrates as a source of FVIII and enzyme-linked immunosorbent assay to search for anti-PEG antibodies. RESULTS: We found inhibitory anti-PEG/anti-PEGylated rFVIII antibodies in 4 patients (5%), both persistent and transient, explaining the impaired recovery. The patients had neutralizing anti-PEG antibodies prior to the first dosing of PEGylated rFVIII. We demonstrated neutralizing antibodies (mainly immunoglobuline G) specific for PEG and all 3 commercially available PEGylated rFVIII products. CONCLUSION: The number of patients with inhibitory anti-PEG antibodies was significant, and the presence of inhibitors against PEGylated rFVIII emphasizes the importance of individual monitoring when switching FVIII concentrates to ensure safety and efficacy of the treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AAdultHumansAntibodies, NeutralizingRecombinant ProteinsHalf-LifePolyethylene Glycols

Stichwörter der Autor:innen

FVIII recoveryPEGylated recombinant FVIII productsextended half-life FVIII productshemophilia Aneutralizing anti-PEG antibodies

Substanzen

Factor VIIIAntibodies, NeutralizingRecombinant ProteinsPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Department of Haematology, Oslo University Hospital, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
  • Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Haematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Haematology, Oslo University Hospital, Oslo, Norway. Electronic address: ragmas@ous-hf.no.

Zitieren

APA

Hillarp, A., Holme, P. A., Wåland, E. P., Le, M. S., Henriksson, C. E., Tjønnfjord, G. E., & Måseide, R. J. (2023). Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.07.019

Vancouver

Hillarp A, Holme PA, Wåland EP, Le MS, Henriksson CE, Tjønnfjord GE, et al. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.07.019

BibTeX
@article{Hillarp2023,
  author = {Hillarp, Andreas and Holme, Pål A and Wåland, Erik P and Le, Marie S and Henriksson, Carola E and Tjønnfjord, Geir E and Måseide, Ragnhild J},
  title = {Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.07.019}
}
Kostenlos starten →